Markers used in the study and allele frequency in the OPRA cohort.

<p>Markers used in the study and allele frequency in the OPRA cohort.</p

<i>CIITA</i> association with rate of bone loss between age 75 and 80.

1<p>CC/CV/VV (c = common, v = variant allele).</p>2<p>Genotypic model.</p>3<p>Adjusted for weight change between age 75 and 80.</p

Associations between BMD and <i>CIITA</i>, <i>CLEC16A</i> and <i>IFNG</i> in the OPRA cohort.

*<p>Only associations where p<0.05 are reported.</p>1<p>BMD values are reported as follows: For single SNP analysis (non-carrriers/carriers or common homozygotes/heterozygotes/variant homozygotes); For haplotypes (non-carriers/carriers); For interactions in allelic models (non-carriers of both variant alleles/carriers of both variant alleles); For interactions in genotypic models, values are given for each marker as common homozygotes/heterozygotes/variant homozygotes since no individuals were carriers of both variant alleles.</p>2<p>For rs3087456 * rs4774 genotypic model, p = 0.011.</p>3<p>For rs3087456 * rs4774 genotypic model, p = 0.028.</p>4<p>CLEC16A haplotype 1: rs725613(T)/rs2903692(G)/rs6498169(A).</p>5<p>IFNG haplotype 4: rs2069727(T)/rs2069718(T)/rs2069705(C).</p

Baseline clinical characteristics of the OPRA and PEAK-25 cohorts.

a<p>Height at age 20 (OPRA), Height at baseline visit, age 25 (PEAK25).</p>b<p>BMD n = 904–946 (OPRA), n = 996–999 (PEAK-25).</p>c<p>QUS n = 853 (OPRA), n = 853 (PEAK-25).</p

Association of <i>CIITA and CLEC16</i> polymorphisms with incident fractures between age 75 and 80 in the OPRA cohort.

1<p>P-values calculated by χ²; adjusted for variables weight and TB BMD at 75y (Any fracture, Osteoporotic fracture) or weight and FN BMD at 75y (Hip fracture).</p>2<p>Osteoporotic fracture sites include hip, vertebrae, distal radius, proximal humerus.</p

Cohort Baseline Details.

<p>Median (Interquartile Range) reported for continuous variables; Number (%) for discrete variables. ^#Current or former smokers; BUA- Broadband Ultrasound Attenuation; SOS- Speed of Sound; CSMI- Cross Sectional Moment of Inertia;</p><p>*Fracture of any type sustained after age 20 and before baseline.</p

Association of rs9939609_<i>FTO</i> with Bone and Body Composition Phenotypes in the PEAK-25 Cohort.

<p>Reported values are median (interquartile range); ^#(TT vs. TA vs. AA) ^aKruskal-Wallis; ^bLinear regression - after adjustment for height and smoking.</p

Genotype and Allele Frequencies.

<p>MAF- Minor allele frequency.</p

SNP <i>rs17782313_MC4R</i> Interacts with Homocysteine to Influence Bone Quality.

<p>Values are median (Interquartile Range);</p>#<p>(TT vs. TC vs. CC);</p>a<p>Kruskal-Wallis;</p>b<p>Linear regression after adjustment for height and smoking.</p

Effect Sizes of Lean and Fat Mass on Bone Quantitative Ultrasound (QUS) Phenotypes.

<p>Reported values are standardized β-coefficients; covariates are adjusted for height and smoking status.</p><p>All coefficients are significant at p<0.01 except for those marked ^a which are non-significant.</p